anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Stimulation is achieved using antibodies that block binding of human CTLA4 to human B7 and diseases amenable to treatment by stimulation and augmentation of prolonging of immune responses include cancers of the prostate, kidney, colon, lung or breast; pathogenic infections; diseases associated with the CNS e.g. amyloidogenic diseases including Alzheimer&#39;s disease; and diseases with inflammatory or allergic components. Diseases amenable to treatment include graft versus host disease, host versus graft disease, allergy, autoimmune diseases and other inflammatory diseases.
An apparatus for displaying icons and warnings about healthcare conditions for a patient through a display screen. The screen may be a touchscreen to facilitate authorized healthcare user interaction. The display screen is located in proximity to a patient or the patient&#39;s room. The display screen provides a public display mode displaying icons and warnings symbol related to one or more conditions for the patient, but without displaying information that may violate the patient&#39;s privacy. The display screen further provides an authorized display mode accessible only by authorized users, such as healthcare workers. Authorized users may thereby gain access to more specific information identifying the one or more conditions, and complete a checklist of healthcare procedures and protocols related to said conditions. Information about authorized user access and checklist completion may be stored to document compliance.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine having excellent decorativeness and a metal film.  &lt;P&gt;SOLUTION: The medicine 1 is formed into a solid shape such as a granular shape or a tablet shape. The metal film 3 composed of an edible metal such as gold, silver or platinum is formed on the surface of the body of the medicine 1 (i.e. the medicine body 2) by sputtering. Thereby, the metal film 3 composed of the edible metal such as the gold, silver or platinum on the surface of the medicine body 2 is formed by the sputtering and the metal film 3 can be homogenized.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide heath foods, pilatory and hair growing agents, aromatherapy materials, cosmetic materials, or the like incorporated with many natural materials gentle to human bodies, such as crude drugs of animal or vegetable origins, aromatic plants and natural nutritious materials using multiple therapies, such as respective herb treatments, aromatic plant treatments and nutritious treatments.  &lt;P&gt;SOLUTION: Crude drugs are provided to hepatic and renal systems according to oriental medicine to activate a function necessary for keeping vital phenomena of human beings or a function of reproduction, growth, aging, bones and bone marrows to increase renal vigor, and promote heath and hair growth. Besides, pharmaceutical effects, psychological effects of aromatics or the like are added by providing aromatic plants. Further, nutrients necessary for human bodies, or essential amino acids and essential fatty acids, vitamins, minerals, and the like which are necessary for synthesis of hair in the body are taken from natural nutritious materials. A procedure for improving actions of living bodies such as a health promoting effect, a hair growth promoting effect and a skin disorder treating effect can be provided by synergistic effects of formulating crude drugs, aromatic plants, and nutritious materials having a high amino acid score.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention relates to a kind of oxirane modification sheath stamen oil antiseptic and preparation method thereof. Preparation method comprises that the hydroxyl adopting in BFEE catalysis sheath stamen oil reacts with epoxyethane ring-expansion polymerization. This preparation method&#39;s synthetic route is simple, and reaction temperature is low, and the reaction time is short. The modification sheath stamen oil antiseptic of preparation has good water-soluble, and has kept the good anti-microbial property of sheath stamen oil itself, and antimicrbial power is strong, has a broad antifungal spectrum, and the term of validity is long, and security is good. This antiseptic can be widely used in the antibacterial anticorrosion of the products such as shampoo, shower cream, hand cleanser, liquid detergent, toner, wet tissue. Effective additive capacity of antiseptic is 1.0～5.0% of product gross mass.
2&#39;3,&#39;-dideoxynucleosides which are effective in inhibiting the infectivity of the human immunodeficiency virus and which are stable in an acidic environment are disclosed, which compounds conform to the formula:   (see fig. I) wherein X is selected from the group consisting of hydrogen, F, CN, N3 and NO2;  Y is either H or F; with the proviso that Y is F only when X=H.      Also disclosed is a compound of the formula:   (see fig. II) Also disclosed are compounds conforming to the formula:     (see fig. III) wherein R may be either OH or NH2; and L is NH2.      Also disclosed are compounds conforming to the formula:   (see fig. IV) wherein A is selected from the group consisting of OH and NH2;      B is selected from the group consisting of H, CH3, CF3, CH=CHBr, and halogen.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use having excellent humectant effect on the skin and suppressed stickiness and giving good feeling to the skin. SOLUTION: This skin preparation contains a mucopolysaccharide and a polymer of 2-methacryloyloxyethylene phosphorylcholine (abbreviated as MPC) as active components. The mucopolysaccharide is one or more substances selected from hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, heparinoid, heparin, etc., and its amount is 0.001-5wt.%, preferably 0.01-3wt.%. The MPC polymer has a molecular weight of &gt;=5,000 and its amount is 0.0001-10wt.%, preferably 0.01-3wt.%. The preparation may be incorporated optionally with other conventional additives and prepared in the form of lotion, cream, powder, etc. The MPC polymer can be produced by reacting MPC of the formula in a solvent in the presence of a polymerization initiator (e.g. 2,2&#39;-azobisisobutyronitrile).
Synthetic polynucleotides comprising a DNA sequence encoding a peptide or protein are provided. The DNA sequence of the synthetic polynucleotides comprise codons optimized for expression in a nonhomologous host. The invention is exemplified by synthetic DNA molecules encoding HIV env as well as modifications of HIV env. The codons of the synthetic molecules include the projected host cell&#39;s preferred codons. The synthetic molecules provide preferred forms of foreign genetic material. The synthetic molecules may be used as a polynucleotide vaccine which provides immunoprophylaxis against HIV infection through neutralizing antibody and cell-mediated immunity. This invention provides polynucleotides which, when directly introduced into a vertebrate in vivo, including mammals such as primates and humans, induces the expression of encoded proteins within the animal.
With the growing prevalence of sleep-tracking wearables available to consumers, understanding the psychological and behavioral impacts they have on users is important. Recent advancements in wearable technology allow for monitoring various sleep parameters, providing users with extensive data on their sleep patterns. The study aims to examine how the presentation of sleep data influences user sleep quality, sleep-related behaviors, including sleepiness, and sleep-related anxiety and stress. It will evaluate how the presentation of sleep data affects individuals\&#39; perceptions of sleep and related health issues, including daytime sleepiness and perceived sleep quality. Participants will receive sleep data feedback based on new methods assessed using Fitbit, brain-sensing earbuds, and other factors that might impact sleep. Additionally, the study seeks to offer valuable insights into sleep research, behavioral psychology, and wearable technology.
The present invention relates to compositions comprising reversibly modified oligonucleotides and uses thereof. Disclosed herein are glutathione-sensitive oligonucleotides and methods of use thereof. Any oligonucleotide of interest can be modified with a glutathione-sensitive moiety, including oligonucleotides for in vivo delivery, such as nucleic acid inhibitor molecules. Typically, the glutathione sensitive moiety is used to reversibly modify the 2&#39; -carbon of the sugar moiety in one or more nucleotides in the oligonucleotide, although other carbon positions may also be modified with the glutathione sensitive moiety. Glutathione-sensitive nucleotides and nucleoside monomers, including glutathione-sensitive nucleoside phosphoramidites, are also disclosed, which are useful, for example, in standard oligonucleotide synthesis methods. In addition, glutathione sensitive nucleotides and nucleoside monomers without phosphoramidites can be used therapeutically, for example, as antiviral agents.
The invention comprises compounds of the general formula &lt;FORM:0889660/IV (b)/1&gt; and their physiologically tolerable acid addition and quaternary ammonium salts, wherein X represents O or H2, A represents an alkylene residue containing 2 to 5 carbon atoms, B represents a dialkylamino group, each alkyl of which contains up to 5 carbon atoms, or an N,N-alkyleneimino group, or an N,N-oxa- or aza-alkyleneimino group, the alkylene residue containing 4 to 6 carbon atoms and each of the benzene rings may be substituted by an alkyl or alkoxy group containing up to 4 carbon atoms, a halogen atom or a tri-fluoro methyl group.  The compounds of the invention may be prepared by introducing the tertiary amino alkyl residue, directly or in stages, into a compound of the general formula &lt;FORM:0889660/IV (b)/2&gt; which may be appropriately substituted in the benzene nuclei and, if desired, reducing the resulting 6,11-diones to the corresponding 6-ones.  Thus a morphanthridine-6,11-dione or -6-one is condensed, desirably in the presence of a condensing agent, with a reactive ester of an alcohol B1-A-OH, where B1 is a tertiary amino group or a residue replaceable thereby or convertible thereinto, and, if necessary, converting or replacing B1 by a tertiary amino group. Morphanthridine-6-one is prepared by hydrogenating the 6,11-dione. Benz-methyl- -chloro- and -methoxy-morphanthridine-6,11-diones are prepared by reacting a substituted anthraquinone with hydrazoic acid. (Two isomers are formed in each case).ALSO:Pharmaceutical preparations comprise compounds of the general formula &lt;FORM:0889660/VI/1&gt; and their physiologically tolerable acid addition salts and quaternary ammonium salts (wherein X represents O or H2, A represents an alkylene residue containing 2 to 5 carbon atoms, B represents a dialkylamino group, each alkyl of which contains up to 5 carbon atoms or an N,N-alkyleneimino group, or an N.N.oxa- or -aza-alkyleneimino group, the alkylene residue containing 4 to 6 carbon atoms and each of the benzene rings may be substituted by an alkyl or alkoxy group containing up to 4 carbon atoms, a halogen atom or a trifluoromethyl group) in admixture or in conjunction with a pharmaceutical carrier suitable for enteral or parenteral administration.  The compositions may be in any conventional form and may contain other therapeutically useful substances.  Acid addition salts are formed from organic or inorganic acids including methionine tryptophane, lysine and orginine.  The compounds possess antispasmodic properties without significant anticholinergic and/or antihistaminic side effects.
1,268,115. Dental filling materials. JOHNSON &amp; JOHNSON. 13 June, 1969 [14 June, 1968], No. 30149/69. Heading C3P. Packaged dental filling materials for preparing cured dental fillings comprise a two-part system, one of said parts being a paste consisting of a binder system comprising a colourless binder monomer which is a bisphenol A derivative having at least two terminal acrylate or methacrylate ester groups, at least 65% by weight of a finely divided filler and a free radical polymerization catalyst; and the other of said parts being a paste containing substantially the same monomer as in the first part, at least 65% by weight of a finely divided filler and an activator for said catalyst. Polymerization is initiated when the two packaged parts are blended together. The preferred binder monomer is that of the formula The viscosity of the monomer can be adjusted by diluting with another monomer such as methyl methacrylate or a glycol dimethacrylate, e.g. triethylene glycol dimethacrylate. Benzoyl peroxide is a suitable catalyst and the activator may be, for example, N,N.dimethyl.p-toluidine or p-toluenesulphinic acid. Preferred as fillers are inorganic materials such as fused silica, aluminium oxide, crystalline quartz and glass beads. The filler may be treated with a keying agent, e.g. an ethylenically unsaturated organosilane, to improve the bond between the polymerized binder and the filler particles. Optional components which may be added include inhibitors such as butylated hydroxy-toluene, U.V. absorbers such as 2-hydroxy-4-methoxy-benzophenone, and submicron particle material, e.g. hydrophobic submicron silica, to prevent possible slight separation between binder monomer and filler. Pigment can be included in one of the parts to obtain any desired colour shade; in the example unspecified organic dyes are used.
To provide a medical appliance and implantation method, the medical appliance being capable of further suppressing a temperature rise of an organ at the time of implanting the organ to a recipient and hardly disturbing work of an operating surgeon.SOLUTION: This organ housing bag 1 comprises a bag-like thermal insulation sheet 10 for holding an organ 9. The thermal insulation sheet 10 includes a pair of water resistant layers and a thermal insulation layer positioned between the pair of water resistant layers. In performing an implantation operation of the organ 9, the organ 9 is disposed into a recipient&#39;s body cavity in a state in which the organ is housed in the organ housing bag 1. Thereby, anastomosis of a blood vessel is enabled while inhibiting a temperature of the organ 9 from being raised by the recipient&#39;s body temperature and an ambient temperature. As a result, occurrence of disorder after the operation can be suppressed by inhibiting the organ 9 from becoming in a warm ischemia state. In addition, because the thermal insulation sheet is formed in a bag shape, an end of the thermal insulation sheet hardly disturbs work of an operating surgeon.SELECTED DRAWING: Figure 1
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an apparatus for making a skin beautiful, which can apply appropriate treatment, for example, even to the nose&#39;s wings with variations in irregularities of a skin surface, and which can apply the treatment capable of adequately bringing about the effect of making the skin beautiful, the effect of closing a person&#39;s pores, the effect of sterilizing the skin surface, etc., while holding down a voltage applied to a discharge tube.  &lt;P&gt;SOLUTION: In this apparatus 1 for making the skin beautiful, an electrode 6 for contact with the skin surface and a vent hole 7 are provided on the periphery of a head part 3. In the electrode 6, a base end is brought into contact with the discharge tube 5 which is embedded in a casing 2, and a tip part 6a is sharply formed and protruded to the outside of the casing 2. The vent hole 7 is opened to the outside of the casing 2 near the electrode 6 through a peripheral part of the discharge tube 5 in the casing 2. Thus, the tip part 6a of the electrode 6, which can converge discharge energy from the discharge tube 5, is brought into contact with a region, for example, wherein the skin is to be made beautiful, so that ozone can effectively act on the skin surface to be subjected to the treatment, through the vent hole 7 and the electrode 6.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Culturing algae from which organosilicon cpds. can be extracted, comprises: (i) removing micro-cuttings from an alga plant; (ii) immersing the cuttings in a tank contg. sea water; (iii) immersing an elongated culture support (e.g. rope) in the tank to allow attachment of the cuttings; and (iv) placing the support in the sea at a predetermined depth and parallel to the surface. Also claimed are new organosilicon cpds. of formula (I) SiR1R2R3R4 when extracted from the reproductive organs and juvenile tissues of algae, whereby R1-R4 are organic gps., at least one being hydrolysable gp. of the type XR&#39; where X is heteroatom (esp. O) and R&#39; is H or organic gp.
An automated allergy office system and method provides a medical professional with a new allergy treatment plan to administer to a patient. The automated allergy office system comprises a viewing device to select a test site on the patient&#39;s skin that is clear. A multiple test applicator is in cooperative engagement with a fluid tray and delivers a small amount of a first allergen to a first test site on the patient&#39;s skin as a small amount of a second allergen is delivered to a second test site on the patient&#39;s skin. The allergy condition of the patient is detected as a wheal forms at the first test site after fifteen minutes. The elements of the treatment plan are retrieved from a database for treating the patient&#39;s allergy condition. The patient&#39;s electronic medical record is checked to confirm that the allergy treatment is new for this patient.
The invention relates to decoction for treating renal calculus and urethral calculus, which belongs to a traditional Chinese medicine for treating the renal calculus and the urethral calculus. The decoction comprises the following raw materials of medicines: yanchuncao and chicken&#39;s gizzard-membrane. The decoction is prepared by adding water into the yanchuncao and the chicken&#39;s gizzard-membrane and decocting for 20 minutes. The decoction has good effect and quick acting for treating the renal calculus and the urethral calculus and can achieve the aims of dissolving calculus, promoting blood circulation, dissolving stasis, promoting urination and removing calculus. The medicine is a purely natural Chinese herbal medicine product, has no toxic or side effect to a human body, is suitable for treating the renal calculus and the urethral calculus, has optimal curative effect and can cure the renal calculus and the urethral calculus by being taken for 2-4 times. The statistics of more than 200 cases of trial shows that the cure after-effect of a patient is good, the total effective rate reaches more than 90%, the cure rate reaches more than 85%, and the invention is suitable for the treatment of the renal calculus and the urethral calculus.
The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini -mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors&#39; belief that within the group of 20 - 26, the memory impairment in the sub-group of 24 - 26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.
Articles and methods for increasing the triplet upconversion threshold, e.g, by utilizing a heavy atom- functionalized triplet exciton upconverter, are generally described. Some embodiments, for example, are directed to articles and methods that use a triplet sensitizer and a heavy atom- functionalized upconverter to produce upconverted photons ( e.g. , light of a second energy). The light may be used to polymerize a polymerizable species. Other upconversion configurations can also be used in other embodiments. In some cases, this may allow true 3D printing to be achieved due to improved control of light absorption,  e.g ., without needing to &#34;print&#34; on a layer- by-layer basis.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a stamina enhancing agent for Japanese that makes use of the function of garlic and red pepper because the people who like these foods are remarkably energetic.  &lt;P&gt;SOLUTION: The waontherapy devised by a professor is well known to be very effective against many illnesses and introduced to hospitals throughout the country. The therapy works well by externally warming a patient body. On the contrary, the garlic and red pepper are intended for use for internally warming a body, and therefore are inhibited to be used to those having a wasting illness. Considering that increase of a basal metabolic rate makes healthy people stronger and is helpful to tonicity and beauty, a small amount of powdered red pepper and powdered garlic are mixed and packed in a capsule.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Plasmid vectors are provided that carry cDNA clones coding for polypeptides exhibiting B-cell, T-cell and mast cell stimulatory activities, all of which are enhanced in the presence of other immune-reactive agents. The polypeptides also augment the activity of various CSF&#39;s, such as G-CSF and G/M-CSF, and depress proliferation of macrophages in the presence of M-CSF. The cDNA is derived from mRNA isolated from a mammalian cell source, such as T-cells typically after activation with a mitogen. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as COS cells. Two expressed polypeptides of the present invention from different mammals are about 140 and 150 amino acids in length, including potential leader sequences. An E. coli culture containing a plasmid (pcD-2A-E3) carrying a mouse cDNA insert of the present invention was deposited with the American Type Culture Collection (A.T.C.C.) on Nov. 18, 1985, and designated accession number 53,330. Two additional E. coli cultures, each carrying plasmids with different human cDNA inserts of the present invention, were deposited with the A.T.C.C. as follows: pcD-2Fl-13 (pcD-46) was deposited on Nov. 26, 1985 and designated accession number 53,337 and pcD-125 was deposited on Mar. 7, 1986 and designated accession number 67,029.